Myriad Genetics (MYGN) Form 4: COO Withholds 1,085 Shares for Taxes

Myriad Genetics insider transaction summary: Chief Operating Officer Mark Verratti reported a compensatory disposition on 09/21/2025 where 1,085 shares of Myriad common stock were disposed of at an average price of $7.77 per share.

Rhea-AI Filing Summary

Myriad Genetics insider transaction summary: Chief Operating Officer Mark Verratti reported a compensatory disposition on 09/21/2025 where 1,085 shares of Myriad common stock were disposed of at an average price of $7.77 per share. The filing explains these shares were withheld by the company to satisfy tax-withholding obligations related to the vesting of restricted stock units. After the withholding, Verratti beneficially owns 381,826 shares directly. The Form 4 was signed on 09/22/2025 and indicates a routine tax-related transaction following equity vesting.

Insights

Securities Analyst

TL;DR: Routine tax-withholding sale by an officer; modest in size relative to reported holdings, limited market impact.

The transaction is labeled as a compensatory disposition tied to RSU vesting and the accompanying explanation confirms shares were withheld to meet tax obligations. The disposed amount (1,085 shares at $7.77) is small relative to the officer's retained position of 381,826 shares, suggesting this is administrative rather than a discretionary cash sale. For investors, this type of Form 4 typically signals no change in insider conviction beyond normal equity compensation mechanics.

Corporate Governance Expert

TL;DR: Administrative withholding after RSU vesting; disclosure is timely and follows Section 16 reporting norms.

The filing is straightforward: it identifies the reporting person, relationship (COO), transaction code, and provides an explanation that withholding was based on the closing price on September 19, 2025. The timely Form 4 and explicit remark about tax-withholding satisfy transparency expectations for insider compensation events. There is no indication of unusual trading patterns or coordinated filings.

Insider Trade Summary

Exercise Price or Tax Liability: 1,085 shares

Exercise Price or Tax Liability 1 txn

Insider Verratti Mark

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,085	$7.77	$8K

Holdings After Transaction: Common Stock — 381,826 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 19, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Myriad Genetics COO Mark Verratti report on Form 4 (MYGN)?

The Form 4 reports a compensatory disposition on 09/21/2025 where 1,085 shares were withheld to satisfy tax-withholding obligations related to RSU vesting.

At what price were the shares disposed of in the MYGN Form 4?

The reported price for the withheld shares is $7.77 per share.

How many Myriad (MYGN) shares does Mark Verratti beneficially own after the reported transaction?

After the tax-withholding disposition, Mark Verratti directly beneficially owns 381,826 shares.

Why were shares disposed of according to the Form 4 for MYGN?

The filing explains the shares were withheld by the company to satisfy tax withholding obligations arising from the vesting of restricted stock units.

When was the Form 4 for Mark Verratti filed/signed?

The Form 4 shows the signature by Justin Hunter for Mark Verratti dated 09/22/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/22/2025 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verratti Mark

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2025		F		1,085(1)	D	$7.77	381,826	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 19, 2025.

Remarks:

	By: Justin Hunter For: Mark Verratti	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.